新検索ページはこちら
ログイン
お問い合わせ
（旧版）前立腺癌診療ガイドライン 2006年版
書誌情報
第3章 治療総論
参考文献
5 薬物療法 ＊この項の文献番号は、「第6章薬物療法」の文献番号と対応しています。
| 1） | Tsushima T, Nasu Y, Saika T, Maki Y, Noda M, Suyama B, Yamato T, Kumon H. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int. 2001;66（3）:135-9. |
| 2） | Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23（4）:808-15. |
| 3） | Wirth M, et al:Bicalutamide（Casodex）150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology, 2001;58:146-51. |
| 4） | See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol 2003;44（5）:512-7;discussion 517-8. |
| 5） | Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K;Scandinavian Prostatic Cancer Group. Bicalutamide（150 mg）versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer:5. 3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol. 2004;172:1871-6. |
| 6） | Medical Research Council Prostate Cancer Working Party Investigators Group:Immediate versus deferred treatment for advanced prostate cancer:initial results of the Medical Research Council Trial. Br J Urol, 1997;79:235-46. |
| 8） | Labrie F, et al:Combination therapy with flutamide and castration（LHRH agonist or orchiectomy）in advanced prostate cancer:a marked improvement in response and survival. J Steroid Biochem. 1985;23:833-41. |
| 9） | Prostate Cancer Trialists' Collaborative Group:Maximam androgen blockade in advanced prostate cancer:an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet. 1995;346:265-9. |
| 10） | Prostate Cancer Trialists' Collaborative Group:Maximal androgen blockade in advanced prostate cancer:an overview of the randomised trials. Lancet. 2000;355:1491-8. |
| 11） | Eisenberger MA, et al:Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-42. |
| 12） | Schmitt B, et al:Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer:a systematic review. Urology. 2001;57:727-32. |
| 13） | Samson DJ, et al:Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361-76. |
| 14） | Klotz L. Combined androgen blockade in prostate cancer:meta-analyses and associated issues. BJU Int 2001;87（9）:806-13. |
| 15） | Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA;TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351（15）:1502-12. |
| 16） | Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and Estramustine Compared with Mitoxantrone and Predonisone for Advanced Refractory Prostate Cancer. N Engl J Med. 2004;351（15）:1513-20. |
